EC
UTHR icon

EntryPoint Capital’s United Therapeutics UTHR Stock Holding History

EntryPoint Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-716
Closed -$228K – 1367
2024
Q2 		$228K Buy
+716
New +$190K 0.11% 335
2024
Q1 		– Sell
-350
Closed -$77K – 1778
2023
Q4 		$77K Buy
+350
New +$80.7K 0.07% 514

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EntryPoint Capital's UTHR Position: Q3 2024 in Review

EntryPoint Capital sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 716 shares — an estimated $228K sold.

EntryPoint Capital first reported a position in UTHR in Q4 2023 and held it in 2 quarters. The position peaked at $228K in Q2 2024. 625 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

  • EntryPoint Capital reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 716 United Therapeutics shares in Q3 2024, an estimated $228K.
  • EntryPoint Capital first reported a position in United Therapeutics in Q4 2023 and held it in 2 quarters.
  • EntryPoint Capital's United Therapeutics position peaked at $228K in Q2 2024.
  • 625 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.